F3/Tissue Factor/Coagulation Factor III/CD142 Drug Discovery Landscape & Assay Solutions
- By admin
- 28 Jul 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor ADC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for F3-targeted drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | F3 (Tissue Factor) ECD-Fc Fusion Protein Human, Cyno, Mouse orthologs. HEK293 expressed (Native Glycosylation). High Purity (>95%, HPLC). Endotoxin <1EU/μg. Sequence Verified. |
View F3 Products |
| Gene Delivery | F3 (Tissue Factor) Lentivirus Premade Particles Full-length ORF (Uniprot P13726) for stable cell line construction. Ideal for internalization & trafficking assays. |
View F3 Products |
| Benchmark Ab | Anti-F3 (Tisotumab Vedotin Biosimilar Sequence) Recombinant human IgG1, Sequence Verified. Positive control for ADC benchmarking. |
View F3 Products |
| Validator | F3 siRNA Set Gene-specific knockdown for on-target specificity verification. |
View F3 Products |
| Ligand Control | F7 (Coagulation Factor VII) Recombinant Protein Native ligand for competitive binding & selectivity assays. |
View F7 Products |
| Pathway Partner | PAR1 (F2R) Recombinant Protein Coagulation cascade signaling partner; relevant for downstream functional studies. |
View F2R Products |
| Related Target | F2RL1 (PAR2) Recombinant Protein Downstream effector in TF-mediated oncogenic signaling. |
View F2RL1 Products |
| Related Target | TFPI (Tissue Factor Pathway Inhibitor) Recombinant Protein Endogenous regulator for pathway balance assays. |
View TFPI Products |
Critical Assay Requirements & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cynomolgus Cross-reactivity for GLP Toxicology | Human/Cyno F3 ECD-Fc proteins with >98% sequence homology, purified to >95% (Theoretical MW confirmed by Mass Spec) |
| ADC Internalization & Trafficking | Full-length F3 Lentivirus particles (HEK293T packaged) for stable expression in cancer cell lines; preserves conformational epitopes for Flow Cytometry |
| Specificity vs Coagulation Cascade (F7 competition) | High-purity F7 ligand protein available for orthogonal binding competition (SPR/BLI) |
| False Positive Control (Off-target cytotoxicity) | Validated F3 siRNA included for knockdown confirmation in high-expressing vs. low-expressing cell models |
| Tumor selectivity vs coagulation safety (epitope mapping) | Human/Mouse/Cyno ortholog proteins with >95% purity; ECD truncations support FVII-competitive vs non-competitive epitope binning |
| Off-target counter-screening | Clinical Benchmark Antibodies (Tisotumab Vedotin biosimilar) included for assay standardization |
Live F3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (Tisotumab Vedotin)
- ➤ Latest Resistance Research (TF-ADC)
- ➤ Recent Patent Filings (TF-Targeting Antibodies)
- ➤ General Clinical Trials for F3
Global Clinical Landscape & Future Outlook
The race for F3/Tissue Factor therapeutics is intensifying, with the approval of Tisotumab vedotin (Tivdak) marking validation of the ADC modality in solid tumors. Major players are shifting focus from first-generation monotherapies to combination regimens with immune checkpoint inhibitors. As TF-targeting drugs expand into ovarian, lung, and pancreatic indications, the next wave of R&D focuses on mitigating bleeding risks through non-coagulant antibody engineering and addressing soluble TF (sTF) sink effects that may limit efficacy. Additionally, epitope-engineered antibodies that decouple anti-tumor activity from systemic coagulation risk are being developed, alongside bispecific formats and radioligand therapies for broader applications. Combination regimens with PD-1/PD-L1 inhibitors and anti-angiogenic agents are expected to define the late-stage pipeline.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Genmab/Seagen/Pfizer (Tivdak), AbbVie (ABBV-706), Miracogen (MRG004A), Exelixis | Cervical, Ovarian, NSCLC, Pancreatic, Solid Tumors | Internalization Assay (Need high-purity ECD-Fc + Lentivirus for live cell imaging) |
| Bispecific | Preclinical Biotechs (TF x CD3) | Solid Tumors (T-cell engagers) | Heterodimer Validation & Cross-species Epitope Mapping (Need Cyno/Mouse Orthologs) |
| Non-coagulant mAb | Academic/Industry Collaborations | Thrombosis (Alternative indication) | F7 Blocking vs. Non-blocking Selectivity (Need F7 protein competitor) |
| Combination Therapy | Pembrolizumab + Tisotumab trials | Cervical (Front-line) | Cell-based reporter assays for immune activation (Need TF-expressing Lentivirus lines) |
| Radioligand Therapy | Early development | Solid Tumors | Binding Affinity (Need high-specific-activity antigen) |
Molecular Differentiation & Assay Strategy
For best-in-class drug development, key differentiation factors include:
- Affinity & Internalization: Moderate affinity (Kd 1–10 nM) for solid tumor penetration; rapid clathrin-mediated endocytosis is essential.
- Epitope specificity: Non-coagulant epitopes that avoid FVII binding are critical for safety; competitive ELISA/SPR with F7 protein used for screening.
- Cross-species reactivity: Human, Cyno, and Mouse orthologs required for tox and efficacy studies; >98% homology between human and cyno.
- CMC stability: High-concentration viscosity screening and accelerated stability testing using ECD-Fc proteins.
Relevant assays: FVII competition, pHrodo internalization, flow cytometry, coagulation interference tests, and target knockdown rescue with siRNA.
Related Targets for Cross-selling
- F7 (Coagulation Factor VII): Essential for competitive epitope binning and safety counter-screening.
- PAR1 (F2R): Key downstream signaling partner in TF/FVIIa axis; used for functional validation.
- F2RL1 (PAR2): Involved in tumor metastasis and inflammation; supports mechanism studies.
- TFPI: Endogenous inhibitor; relevant for resistance and biomarker studies.